Prevention of bacterial growth and biofilm formation by ligands that act on cannabinoidergic systems
A group of antimicrobial compounds shows effectiveness for preventing bacterial growth and bio film formation. In particular, the compounds are effective for preventing the growth of gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (“MRSA”) bacteria. The compounds include naturally-occurring compounds such as linoleyl ethanolamide, noladin ether, and anandamide, and man-made compounds such as CP55,640 [(−)-cis-3-[2-Hydroxy-4-(l,l-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol] and O-2050 [(6aR,10aR)-3-(l-Methanesulfonylamino-4-hexyn-6-yl)-6a,7,10,1Oa-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran]. Because these antibacterial compounds have unique modes of action and/or unique chemical scaffolds compared to traditional antibiotics, they are extremely useful against bacteria having resistances to antibiotics.
1. A method of inhibiting or reducing gram positive bacterial growth or gram positive bacterial biofilm formation on a surface in need of an anti-infective treatment, comprising:
locating the surface in need of the anti-infective treatment; and
contacting the surface in need of the anti-infective coating treatment with an effective amount of a cannabinoidergic-system-acting compound dissolved in an appropriate solvent for inhibiting or reducing gram positive bacterial growth or gram positive bacterial biofilm formation,
wherein the cannabinoidergic-system-acting compound comprises (−)-cis-3-[2-Hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol having a structure of:
2. The method of claim 1 , wherein the cannabinoidergic-system-acting compound, inhibits or reduces the growth of methicillin-resistant Staphylococcus aureus (“MRSA”) bacteria on the surface in need of the anti-infective treatment.
3. A method of inhibiting or reducing the growth of gram positive bacteria and gram positive bacterial biofilm on a surface in need of an anti-infective treatment, the method comprising:
locating the surface of the anti-infective treatment; and
contacting a cannabinoidergic-system-acting compound dissolved in an appropriate solvent at a concentration of at least about 30 μM with the surface in need of the anti-infective treatment,
wherein the cannabinoidergic-system-acting compound is selected from the group consisting of: linoleyl ethanolamide:
O-2050:
Noladin ether:
Anandamide:
a mixture thereof.
4. The method of claim 3 , wherein the surface in need of the anti-infective treatment comprises a medical device surface.
5. The method of claim 4 , wherein the medical device surface comprises: a catheter, hemodialysis equipment, a pulmonary ventilator, a heart valve device, dialysis equipment, surgical equipment, a bandage, or a wound dressing material.
6. A method of preventing bacterial biofilm formation caused by S. epidermidis on a surface in need of an anti-infective treatment, comprising:
locating the surface in need of the anti-infective treatment; and
contacting the surface in need of the anti-infective treatment with an effective amount of a cannabinoidergic-system-acting compound dissolved in an appropriate solvent for inhibiting or reducing gram positive bacterial growth or gram positive bacterial biofilm formation,
wherein the cannabinoidergic-system-acting compound comprises
(−)-cis-3-[2-Hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol having a structure of:
O-2050, having the structure:
mixtures thereof.
7. A method of inhibiting or reducing the growth of gram positive bacteria and gram positive bacterial biofilm on a surface in need of an anti-infective treatment, the method comprising:
locating the surface in need of the anti-infective treatment; and
contacting the surface in need of the anti-infective treatment with an effective amount of a cannabinoidergic-system-acting compound dissolved in an appropriate solvent for inhibiting or reducing gram positive bacterial growth or gram positive bacterial biofilm formation, wherein the cannabinoidergic-system-acting compound is: O-2050: